In a randomized clinical trial by Gordon et al.30, adalimumab treatment targeted for TNFα neutralization achieved <80% PASI reduction on average at week 8, and approximately 60% of patients with psoriasis achieved PASI75 at week 8 with infliximab treatment, which was reported by Kristian et al.31. The gene discussed is TNF; the disease is psoriasis.